Israeli Pharma Firm NeuroRx Completes SPAC Merger at $1.5B Valuation
By NoCamels Team
May 31, 2021 2 minutes
Health & ScienceNews Briefs
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses CDC/ Alissa Eckert, MS; Dan Higgins, MAM. Wikimedia Commons
Israeli clinical-stage small molecule pharmaceutical company NeuroRx has announced the completion of a merger with Big Rock Partners Acquisition Corporation, a special purpose acquisition (SPAC) company. The company will trade on the NASDAQ as NRXP.
The deal is estimated to be worth a $1.5 billion valuation, the Haifa-based company said.
Founded in 2014, NeuroRx is a clinical-stage small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary disease. The company’s two primary medicines are ZYESAMI (aviptadil), an application for COVID-19-related